Fully reversing established arterial calcification is not yet possible with any proven treatment. What is possible, based on current evidence, is slowing its progression, stabilizing dangerous plaques, and reducing the cardiovascular risk that calcification represents. That distinction matters because your calcium score going down isn’t necessarily the goal. Making the calcium in your arteries less likely to cause a heart attack or stroke is.
Why Calcification Is Hard to Undo
Arterial calcification isn’t just calcium randomly sticking to artery walls. It’s an active biological process that resembles bone formation. When the smooth muscle cells lining your arteries are exposed to certain triggers, particularly high phosphate levels, they transform into bone-like cells that actively deposit calcium crystals called hydroxyapatite. Lab studies show this transformation kicks in when phosphate concentrations rise above a specific threshold, with calcification increasing in a dose-dependent way as levels climb.
Once those calcium deposits are embedded in plaque, dissolving them without damaging the artery wall is extremely difficult. This is why the medical focus has shifted from “removing calcium” to “making calcified plaques safer and stopping new deposits from forming.”
The Statin Paradox: Higher Scores, Lower Risk
If you’re on a statin and your calcium score went up, that doesn’t necessarily mean things got worse. Statins actually increase plaque density, which paradoxically raises the Agatston calcium score because the scoring system gives extra weight to denser calcium. But denser, more calcified plaques are more stable. They’re less likely to rupture and cause a heart attack than soft, fatty plaques with thin caps.
According to the American College of Cardiology, statin therapy “modestly accelerates calcification of plaques leading to more stable, lower-risk compositions.” So a rising calcium score on statins can actually reflect a plaque that’s being reinforced rather than one that’s becoming more dangerous. Your calcium score still predicts risk even on statins, but the relationship is weaker than in people who’ve never taken them.
Vitamin K2 and Calcium Regulation
Your body has a natural system for keeping calcium in bones and out of arteries. A protein called Matrix Gla Protein (MGP) is one of the strongest inhibitors of arterial calcification in the body, but it only works when activated by vitamin K2. Without enough K2, MGP stays in its inactive form and can’t do its job.
Clinical trials have tested vitamin K2 supplementation (specifically the MK-7 form) at doses ranging from 180 to 720 micrograms per day. A dose-dependent decrease in inactive MGP has been observed, meaning higher doses activate more of this protective protein. The Danish AVADEC trial tested 720 micrograms of MK-7 daily alongside vitamin D for two years and found the combination appeared to slow the progression of coronary calcification, particularly in patients with severe calcification (calcium scores above 400). It didn’t reverse existing deposits, but slowing progression in heavily calcified arteries is a meaningful outcome. A larger trial using the same dosing protocol is currently underway to confirm these findings.
Magnesium’s Protective Role
Magnesium is one of the most accessible and well-supported nutritional factors in calcification prevention. Data from the Framingham Heart Study found that every additional 50 milligrams per day of magnesium intake was associated with 22% lower coronary artery calcification. People in the highest intake group (median of about 427 mg/day) had 58% lower odds of having any coronary calcification at all compared to those in the lowest group (around 259 mg/day).
Magnesium competes with calcium at the cellular level, and adequate levels help prevent the kind of mineral imbalance that triggers calcification. Most adults in the U.S. fall short of the recommended 400 to 420 mg daily for men and 310 to 320 mg for women. Good dietary sources include pumpkin seeds, almonds, spinach, black beans, and dark chocolate. Getting your intake into that upper range through food or supplementation is one of the simplest steps with the strongest evidence behind it.
Phosphate: The Trigger to Manage
High phosphate levels are one of the most direct drivers of arterial calcification. In lab studies, smooth muscle cells cultured at normal phosphate concentrations show no calcification at all, but when phosphate rises even modestly above that threshold, calcification begins and worsens the higher it goes. This is why calcification is so common and severe in people with chronic kidney disease, whose kidneys can’t clear phosphate efficiently.
Even with normal kidney function, a diet very high in phosphate additives (common in processed foods, colas, and processed meats) can push levels in the wrong direction. Reducing your intake of phosphate-heavy processed foods is a practical step. If you have kidney disease, phosphate management through diet and sometimes medication is a central part of preventing calcification from worsening.
Chelation Therapy: What the Evidence Shows
EDTA chelation therapy, which involves intravenous infusions of a compound that binds minerals, has a complicated reputation. The NIH-funded TACT trial (Trial to Assess Chelation Therapy) provided the most rigorous data available. Overall, patients receiving chelation had an 18% reduced risk of subsequent cardiac events compared to placebo. Cardiac events occurred in 26% of the chelation group versus 30% of the placebo group.
The results were more striking in patients with diabetes: those receiving chelation had a 43% lower rate of death from any cause, with cardiac events occurring in 25% of the chelation group versus 38% on placebo. A follow-up trial, TACT2, has been conducted to see if these results hold up. Chelation remains outside mainstream cardiology guidelines, though, and isn’t widely available. It’s also unclear whether the benefit comes from reducing calcification specifically or from other effects like removing toxic metals.
Medical Treatments on the Horizon
One of the more promising approaches in development is SNF472, an intravenous drug that directly blocks the formation of hydroxyapatite crystals (the calcium deposits in arteries) by binding to the crystal surface. In early clinical trials with dialysis patients, it inhibited crystal formation in blood samples by 70 to 80%. Phase 2 trials have been testing whether this translates to slowed calcification progression over 12 months.
Sodium thiosulfate is another compound already used in specific clinical settings. It works by binding calcium into a highly soluble form (calcium thiosulfate) that the body can clear. It’s primarily used for calciphylaxis, a severe and painful condition involving calcification in small skin blood vessels, typically in dialysis patients. It’s administered intravenously, usually 25 grams three to four times per week alongside dialysis. Its use for general arterial calcification remains off-label and limited to specialized settings.
The Exercise Paradox
Regular physical activity remains one of the best things you can do for cardiovascular health overall, but there’s a genuine paradox with calcification scores. Multiple studies have found that people who exercise at very high volumes, particularly endurance athletes, tend to have higher calcium scores than sedentary individuals. In one study of over 25,000 adults, the most physically active group had higher baseline calcium scores and greater five-year progression than inactive participants. Another study found that lifelong exercisers logging more than 2,000 MET-minutes per week had significantly higher calcium scores (9.4 versus 0.6 to 0.9) and a 68% prevalence of detectable calcification.
The critical nuance: exercise intensity appears to matter more than volume, with very vigorous exercise showing the strongest association with calcium progression. And, similar to the statin paradox, the calcification in highly active people tends to be denser and more stable. These individuals still have lower overall cardiovascular event rates despite higher scores. Moderate exercise remains protective across every measure. If you’re a serious endurance athlete with a high calcium score, it’s worth discussing with a cardiologist, but it’s not a reason to stop exercising.
A Practical Approach
Given that full reversal isn’t currently achievable, the practical strategy combines slowing progression with reducing the risk that existing calcification poses. The steps with the strongest evidence behind them:
- Increase magnesium intake to at least the recommended daily amount (400+ mg for men, 310+ mg for women), ideally through magnesium-rich foods.
- Consider vitamin K2 supplementation in the MK-7 form. Clinical trials have used 180 to 720 micrograms daily, with higher doses showing greater activation of the body’s natural calcification-blocking protein.
- Reduce processed food intake to limit phosphate additives that promote calcification.
- Maintain moderate, consistent exercise rather than extreme endurance training if calcification is a concern.
- Address standard risk factors like blood pressure, blood sugar, and cholesterol. Statins, despite raising calcium scores, make existing plaques more stable and reduce event risk.
If you have a calcium score and want to track changes, repeat scans are typically done at intervals of three to five years. The goal isn’t necessarily to see that number drop. It’s to see that progression has slowed and that your overall cardiovascular risk profile is improving.